Almirall
| 150px | |
| Public (Mercado Continuo: ALM-MC: ALM) | |
| Founded | 1943 |
| Founder | Antonio Gallardo Carreras |
| Headquarters | Ronda del General Mitre, 151 08022 Barcelona Spain |
|
Area served
|
International |
| Products | Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Plusvent, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Toctino, Constella, Actikerall.[1] |
|
Number of employees
|
3000 (2013)[2] |
| Website | www.almirall.com |
Almirall, S.A. (Ticker Bolsa de Madrid: ALM) is a pharmaceutical company, with headquarters in Barcelona, founded in 1943 and dedicated to providing medicines through its own R+D, agreements and alliances.[3]
In 2013, it generated total revenue of 825 million € and became the leading pharmaceutical company in R&D investment in Spain and the 4th out of all sectors.[4]
With over 3,000 employees (2013),[2] it has a presence, through its 15 affiliates[5] in Europe, USA, Canada and Mexico.
History
1943 Foundation of Laboratorios Almirall SA.
1979 Launch of the gastroprokinetic clebopride in Spain, the first product from the company’s internal research to obtain a license in another country.
1984 Launch of the antacid almagate in Spain.
1985 Launch of the local anti-inflammatory piketoprofen in Spain.
1990 Launch of the antihistamine ebastine and the gastroprokinetic cinitapride in Spain. Opening of the affiliate in Belgium.
1992 Launch of the anti-inflammatory aceclofenac in Spain.
1993 Opening of the affiliate in Portugal.
1994 Opening of the new headquarters of Almirall in Barcelona.
1995 Inauguration of the extension and remodelling of the pharmaceutical plant in Sant Andreu de la Barca (Barcelona).
1997 Merger of Almirall and Prodesfarma.
2000 Approval of the marketing of the anti-migraine agent almotriptan by the FDA. This is the first medicine with Spanish R&D to receive approval by the FDA.
2001 Opening of the affiliate in Mexico and acquisition of the French affiliate.
2002 Opening of the affiliate in Italy.
2003 Opening of the affiliate in Germany.
2005 Almirall obtains the commercial rights for Sativex in Europe for the treatment of spasticity associated to multiple sclerosis.
2006 Inauguration of the new R&D Centre in Sant Feliu de Llobregat (Barcelona, Spain). Acquisition of the Centre of Excellence for Inhalation Technology.
2007 Stock market flotation and trading on the continuous market in Spain. Acquisition of Hermal, European company specialized in dermatology, from Reckitt Benckiser. Acquisition of a portfolio of eight products from Shire plc.
2008 Opening of affiliates in Austria, Poland, United Kingdom-Ireland and Switzerland.
2010 Opening of affiliate in the Nordic Countries.
2011 Almirall launches Actikerall prescribed for the local treatment of actinic keratosis.
2012 Opening of the affiliate in Canada. Launch of aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the USA under the brand Tudorza Pressair. Launch of Monovo for the treatment of inflammatory skin diseases such as psoriasis.
2013 Acquisition of Aqua Pharmaceuticals, the USA company specialized in dermatology. Launch of linaclotide in Europe (Constella) for irritable bowel syndrome with constipation (IBS-C).
2014 Almirall transfers to Astrazeneca the rights of its respiratory franchise.
2015 Almirall declares its strategic intention to become a leading pharmaceutical company in the field of Dermatology worldwide
Activities
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the USA. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Centres
The company has two R&D centres distributed in Spain and Germany. The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.
The company also has two production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek);[2] as well as 15 affiliates in Germany, Austria, Belgium-Luxembourg, Canada, the USA, France, the Netherlands, Italy, Mexico, the Nordic Countries, Poland, Portugal, the United Kingdom-Ireland, Spain and Switzerland.[2]
Numbers
| 2010 | 2011 | 2012 | 2013 | |
|---|---|---|---|---|
| Total revenue | €1002,1 MM | €873,1 MM | €900,2 MM | €825,5 MM |
| Net sales | €882,4 MM | €768,4 MM | €682,9 MM | €692,9 MM |
| % International sales | - | 50% | 60% | 62% |
| % Sales of own medicines | - | - | 59% | 64% |
| Investment in R&D [6] | 16,4% of net sales | 18,8% of net sales | 23,4% of net sales | 18% of net sales |
| Employees | 2831 | 2765 | 2871 | 3000 |
| Affiliates | 13 | 13 | 14 | 15 |
| R&D Centres [7] | 3 | 3 | 3 | 3 |
| Production centres | 3 | 3 | 3 | 3 |
Main Products
| Brand | Active ingredient | Pathology |
|---|---|---|
| Ebastel | Ebastine | Allergy |
| Monodox | Doxycycline | Severe Acne |
| Acticlate | Doxycycline Hyclate | Severe Acne |
| Almogran | Almotriptan | Migraine |
| Tesavel & Efficib | Sitagliptin and Sitagliptin + Metformin | Diabetes |
| Plusvent | Salmeterol / Fluticasone | COPD |
| Solaraze | Diclofenac sodium | Actinic keratosis |
| Airtal | Aceclofenac | Musculoskeletal pain |
| Decoderm | Fluprednidene | Fungal dermatitis |
| Cordran | Fludroxycortide | Inflammation and itching of the skin |
| Parapres | Candesartan | Hypertension |
| Almax | Almagate | Acidity |
| Balneum | Urea | Dry skin |
| Cleboril | Clebopride | Gastroesophageal reflux disease |
| Actikerall | 5-Fluorouracil / Salicylic Acid | Actinic keratosis |
| Sativex | THC / Cannabidiol | Spasticity in Multiple Sclerosis |
| Constella | Linaclotide | IBS-C |
| Monovo | Mometasone | Psoriasis |
| Toctino | Alitretinoin | Severe chronic hand eczema |
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />External links
- ↑ Products «Products of Almirall S.A.» Retrieved 17th December 2014
- ↑ 2.0 2.1 2.2 2.3 Almirall «What is the size of Almirall's overall workforce?» Retrieved 30 July 2014
- ↑ Almirall «History» Retrieved 18 December 2014
- ↑ Almirall «Almirall's annual reports» Retrieved 18 December 2014.
- ↑ Almirall «Almirall around the World» Retrieved 17th December 2014
- ↑ Partnering and Collaboration «Partnering and Collaboration» Retrieved 18 December 2014
- ↑ R&D in Key Therapeutic Areas «R&D in Key Therapeutic Areas» Retrieved 18 December 2014
- Pages with reference errors
- Pages with broken file links
- Pages using infobox company with unsupported parameters
- Companies of Spain
- Biotechnology companies
- Biotechnology companies of Spain
- Pharmaceutical companies of Spain
- Companies based in Barcelona
- Companies listed on the Madrid Stock Exchange
- Companies established in 1943
- 1943 establishments in Spain
- Spanish brands
